Executive summary

The Data Analysis and Real World Interrogation Network (DARWIN EU^®) gives sponsors a growing view of the real-world evidence questions European regulators are asking, the approved data sources they select, and the methods and feasibility constraints that shape their work. The strategic opportunity is to move beyond study-by-study monitoring and use recurring patterns to anticipate evidence needs earlier. IQVIA Regulatory Science & Strategy (RSS) uses the DARWIN EU Insight Navigator to organize public outputs into traceable, strategy-ready intelligence. The Navigator combines structured synthesis with in-house regulatory expertise to help users interpret precedent, identify meaningful patterns, and consider implications for regulatory questions, study design, feasibility, evidence gaps, and cross-functional planning while preserving links to underlying sources.

What is DARWIN EU?

DARWIN EU is a capability established by the European Medicines Agency (EMA) and the European Medicines Regulatory Network to generate timely, reliable real-world evidence from healthcare databases for medicines regulation across the product lifecycle. EMA provides strategic direction, funding, and oversight, while a coordination center currently operated by Erasmus University Medical Center Rotterdam works with a distributed network of data partners. These data come from sources such as hospitals, registries, insurance claims, and biobanks are standardized using the Observational Medical Outcomes Partnership common data model and analyzed locally using standardized methods. As of 2026, DARWIN EU includes 40 data partners across 18 European countries and provides access to data covering approximately 250 million patients. It is used to conduct regulator-requested, non-interventional research on drug utilization, disease epidemiology, medicines safety and effectiveness, and study design and feasibility, with the resulting reports complementing other evidence used by EMA committees and national regulators to inform regulatory reviews, labeling changes, pharmacovigilance, public-health preparedness, and medicines-shortage monitoring.

Why DARWIN EU matters now

DARWIN EU is a federated network of European healthcare data sources supporting regulator-led, non-interventional studies. It expands the traditional sponsor-led model by enabling regulators to generate evidence on safety, utilization, effectiveness, feasibility, and other public-health priorities.

DARWIN EU is distinct from, but complementary to, the HMA-EMA Catalogues, which register studies and data sources from sponsors, researchers, and other networks. DARWIN EU studies are commissioned by EMA and national competent authorities, then executed through a federated common-data-model network using local, privacy-by-design analysis. Its protocols, phenotype definitions, codelists, and analytical code therefore provide direct signals of regulatory priorities and reusable technical references for evidence planning.

DARWIN EU therefore offers real-world evidence precedent generated at regulators’ request and not merely sponsor-led examples or analogues. With IQVIA data partners already approved within the network, IQVIA is well positioned to support sponsors with preparatory analyses and predictive work ahead of an official DARWIN EU study, without implying regulatory endorsement or predetermining its findings.

As studies, data partners, methods, and public resources accumulate, they form a record of regulators’ questions, chosen data sources, analytical approaches, and unresolved gaps. The portfolio offers greater strategic value than any single study viewed alone.

This transparency also creates a practical challenge. Relevant material is dispersed across protocols, reports, dashboards, methodological documents, phenotype libraries, code repositories, and public summaries. Reviewing each source separately is time-intensive and makes cross-study trends difficult to detect as the portfolio grows.

A portfolio-level view enables broader strategic analysis. Teams can assess which regulatory topics receive sustained attention, which European databases prioritize particular objectives, which phenotypes and outcomes recur, where feasibility limitations arise, and which designs and analytical approaches are used consistently across regulatory contexts.

Five intelligence streams sponsors can use

The DARWIN EU Insight Navigator

DARWIN EU protocols, reports, and supporting resources are publicly available, but access alone does not show which precedents are most relevant, how findings should be interpreted in context, or what they may imply for a sponsor’s evidence strategy. IQVIA RSS’s DARWIN EU Insight Navigator (Navigator) provides an expert-informed interpretive layer that organizes these materials around sponsor decisions rather than document storage. The Navigator connects related studies, methods, data choices, and constraints to clarify their collective implications for evidence planning, complementing rather than replacing existing regulatory intelligence resources.

The Navigator quickly maps regulator-led activity within a therapeutic area, compares how similar research questions were addressed, and identifies recurring endpoints, cohort definitions, and methodological choices. Database selection patterns also highlight concerns about completeness, timeliness, representativeness, data quality, or sample size that warrant further feasibility work before protocol finalization.

Because the Navigator informs consequential planning decisions, its output must be defensible. Each insight is traceable to a public source, distinguishes evidence from interpretation, and uses consistent attributes for meaningful comparison. Privacy-by-design use of study-level information and expert oversight also prevent AI-enabled synthesis from obscuring context or overstating conclusions.

The IQVIA contribution extends beyond extracting study attributes. In-house regulatory experts help assess the purpose and context of each study, evaluate the relevance and limitations of apparent precedents, distinguish recurring signals from isolated examples, and connect findings to sponsor-specific development questions. This expert review reduces the risk that public information is applied without the qualifications needed for sound regulatory and evidence-planning decisions.

How users apply the Navigator

Case Study

One completed sponsor engagement provides a successful proof point for this approach. IQVIA analyzed regulator-initiated DARWIN EU studies and their underlying evidence questions across major metabolic diseases, rare diseases, and other therapeutic areas with important safety and utilization questions. This work gave the sponsor forward-looking insight into how EMA is using real-world evidence to investigate comparable patient populations, treatment patterns, data feasibility, safety, and disease characteristics. Such insight offered early indications of potential regulatory areas of interest before they emerge as formal feedback or requests. The value extended beyond describing DARWIN EU: IQVIA translated patterns across therapeutic areas into actionable regulatory intelligence for the sponsor’s own products and development programs. The analysis helped the sponsor anticipate questions regulators may investigate independently, identify potential evidence gaps or areas of scrutiny, and proactively consider how available real-world evidence could support future regulatory interactions and evidence-generation planning.

From retrospective awareness to proactive planning

The Navigator supports earlier, more consistent cross-functional decisions by helping teams anticipate regulatory questions, benchmark study concepts, and identify suitable data sources and execution risks. By connecting studies across the portfolio, it reduces duplication and redesign while helping users interpret which signals matter, their limitations, and the decisions they may inform.

References and source notes

1. European Medicines Agency. Real-world evidence. https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence

2. DARWIN EU. Official website and public study resources. https://darwin-eu.org/

3. European Medicines Agency. Third report on the real-world evidence framework, February 2024 to February 2025. https://www.ema.europa.eu/system/files/documents/report/3rd-rwd-study-report-feb-2024-feb-2025-v40_en.pdf

About the authors

ELIZABETH SZYMANSKI is an Associate Consultant in Regulatory Science & Strategy at IQVIA. Her work supports regulatory evidence strategy, real-world evidence planning, and the synthesis of regulatory intelligence for sponsor decision-making.

TIFFANY MERCADO is an Associate Principal in Regulatory Science & Strategy at IQVIA. Her expertise spans regulatory science, innovative trial design, regulator interactions, device and drug approval strategy, total life cycle evidence generation, regulatory landscaping, real-world evidence, and biomarker qualification.